WALTHAM, Massachusetts, September 15 /PRNewswire/ --
- Interviewed Experts Lack Confidence in Malignant Melanoma Cancer Vaccines as a Result of Recently Published Data, According to a New Report from Decision Resources
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the malignant melanoma drug market, driven by the launch of emerging agents, will experience robust annual 12 percent growth through 2012 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.